Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 29;12(8):e0183949.
doi: 10.1371/journal.pone.0183949. eCollection 2017.

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

Allan A Lima Pereira  1 , Maria Pia Morelli  1 , Michael Overman  1 , Bryan Kee  1 , David Fogelman  1 , Eduardo Vilar  2 , Imad Shureiqi  1 , Kanwal Raghav  1 , Cathy Eng  1 , Shanequa Manuel  1 , Shadarra Crosby  1 , Robert A Wolff  1 , Kimberly Banks  3 , Richard Lanman  3 , AmirAli Talasaz  3 , Scott Kopetz  1 , Van Morris  1
Affiliations

Clinical utility of circulating cell-free DNA in advanced colorectal cancer

Allan A Lima Pereira et al. PLoS One. .

Abstract

Background: Circulating cell-free DNA (cfDNA) isolated from the plasma of cancer patients (pts) has been shown to reflect the genomic mutation profile of the tumor. However, physician and patient assessment of clinical utility of these assays in patients with metastatic colorectal cancer (mCRC) has not been previously described.

Methods: Patients were prospectively consented to a prospective genomic matching protocol (Assessment of Targeted Therapies Against Colorectal Cancer [ATTACC]), with collection of blood for cfDNA extraction and sequencing of a 54-gene panel in a CLIA-certified lab. Formalin-fixed, paraffin-embedded (FFPE) tissue from prior resections or biopsies underwent 50-gene sequencing. Results from both assays were returned to the treating physicians for patient care and clinical trial selection. Follow-up surveys of treating physicians and chart reviews assessed clinical utility.

Results: 128 mCRC pts were enrolled between 6/2014 and 1/2015. Results were returned in median of 13 and 26 days for cfDNA and FFPE sequencing, respectively. With cfDNA sequencing, 78% (100/128) of samples had a detectable somatic genomic alteration. 50% of cfDNA cases had potentially actionable alterations, and 60% of these could be genomically matched to at least one clinical trial in our institution. 50% (15/30) of these pts enrolled onto an identified matched trial. Physicians reported that the cfDNA testing improved the quality of care they could provide in 73% of the cases, and that 89% of pts reported greater satisfaction with the efforts to personalize experimental therapeutic agents.

Conclusions: cfDNA sequencing can provide timely information on potentially actionable mutations and amplifications, thereby facilitating clinical trial enrollment and improving the perceived quality of care.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: KB, RL, and AT are employees of and hold equity in Guardant Health, Inc. All the other authors declare no conflicts of interest in the authorship or publication of this contribution. Three coauthors are employees of and hold equity in Guardant Health, which provided support in the form of salaries for these co-authors. However, this commercial affiliation did not have any role in the data collection and analysis. These co-authors contributed with study design, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Number of patients with genomic alterations detected by both FFPE and cfDNA analysis.
FFPE = formalin-fixed, paraffin-embedded tissue; cfDNA = cell-free DNA; Amplif = amplification.
Fig 2
Fig 2. Clinical utility of cfDNA sequencing results.
(A) Detectable mutations and/or amplification were present in 78% of patients. (B) 50% of these patients (N = 50) had “potentially actionable” mutations and/or amplifications. (C) Among these, 60% (N = 30) patients had a clinical trial identified based on the matched biomarker detected from the cfDNA (D) 15 patients ultimately enrolled on a biomarker-based clinical trial. Pt = patient; MDACC = MD Anderson Cancer Center.
Fig 3
Fig 3. Provider survery results.
Physician preference for convenience (A) and clinical utility (B) according to the sample detection method and a stated desire to incorporate sequencing results into clinical decisions. FFPE = formalin-fixed, paraffin-embedded tissue; cfDNA = cell-free DNA.
Fig 4
Fig 4. The impact of the use of cfDNA in (A) quality of care and (B) patient satisfaction.
See this image and copyright information in PMC

References

    1. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80. Epub 2007/10/11. doi: 10.1200/JCO.2007.11.0833 . - DOI - PubMed
    1. Booth CM, Nanji S, Wei X, Mackillop WJ. Outcomes of Resected Colorectal Cancer Lung Metastases in Routine Clinical Practice: A Population-Based Study. Ann Surg Oncol. 2016;23(4):1057–63. Epub 2015/11/18. doi: 10.1245/s10434-015-4979-0 . - DOI - PubMed
    1. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. Epub 2008/06/04. doi: 10.1245/s10434-008-9966-2 . - DOI - PubMed
    1. Allegra CJ, Rumble RB, Schilsky RL. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016;12(2):180–1. doi: 10.1200/JOP.2015.007898 . - DOI - PubMed
    1. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016. Epub 2016/04/25. doi: 10.1016/S1470-2045(16)00150-9 . - DOI - PubMed